Our next our annual IMS user group event will take place in September, more details to follow.
Our quarterly report which shows your IMS data in three distinct cohort groups, includes activity for the fourth quarter of the 2017-18 year and all activity for the last four quarters. Available on the 'Quarterly Reports' tab.
The annual report for the Integrated Monitoring System (IMS) details all activity across Cheshire and Merseyside for individuals in contact with drug or alcohol treatment/low threshold or syringe exchange services.
We have a new name, the research centre formerly the Centre for Public Health has been granted Institute status.
This year's annual IMS user group event will place on the 14th September 2018, at Liverpool John Moores University.
More details and a registration link for the event will be available on the IMS user group event page soon.
"The number of individuals engaged in structured drug treatment programmes in England has declined over recent years, but this has been a trend which has occurred alongside another development, that of an increasing number of drug related deaths (DRDs), culminating last year with ONS reporting the highest number of DRDs on record. Delivery of needle and syringe programmes (NSP) in England is not monitored in the same way as drug treatment programmes, at least at a national level, but local monitoring systems provide information which points to a different picture than that which national drug treatment programme data might suggest."
The drug strategy sets out how the government and its partners, at local, national and international levels, will take new action to tackle drug misuse and the harms it causes.
Posted: 14 July 2017
RSPH are calling for measures aimed at moving UK drugs strategy away from a predominantly criminal justice approach towards one based on public health and harm reduction. Their report 'Taking a New Line on Drugs' proposes a new approach to UK drug policy, featuring opinion from PHI director Jim McVeigh.
Posted: 16 June 2016
Naloxone is the emergency antidote for overdoses caused by heroin and other opiates/opioids (such as methadone and morphine). The main life-threatening effect of heroin and other opiates is to slow down and stop breathing. Naloxone blocks this effect and reverses the breathing difficulties. On the 1 October 2015, new regulations came into force, which allows for widening of the availability of naloxone.
Posted: 10 November 2015
PHE briefing for local commissioners who are responsible for commissioning services to prevent and treat harms caused by image and performance enhancing drugs (IPEDs) and injecting drug use.
Posted: July 2015
The National Institute for Health and Care Excellence (NICE) has issued three new quality standards (QS82, QS83 & QS84) to encourage healthy living and reduce harm from smoking, alcohol and physical inactivity.
Posted: March 2015
PHE briefing regarding legal changes allowing the provision of foil by drug treatment and needle syringe exchange providers.
Posted: August 2014
NICE public health guidance update(PH52) containing recommendations on needle and syringe programmes
Posted: April 2014
Best practice guidance from the National Treatment Agency (NTA) for commissioners and providers of pharmaceutical services for drug users.
Posted: February 2006
Your session will expire in
minutes due to inactivity.
Please click the button below if you are still using the application.